BRIEF-Immune Design gets positive FDA feedback on Phase 3 clinical trial design for CMB305
October 16, 2017 at 16:38 PM EDT
* Immune Design announces positive FDA feedback on Phase 3 clinical trial design for CMB305 in synovial sarcoma patients
